BSX

TentativeAI MemoPost-earnings T+3

Boston Scientific

As of 2026-08-03/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 beat company guidance • 2026-07-29

Base target: $52 / p=55% prob

Biggest risk

WATCHMAN referral changes, EP competition and the reported weaker second-half outlook create meaningful execution and estimate risk; the 2027 challenge comes from secondary stored earnings-call coverage.

Invalidation

Break below $42 or thesis failure.

What would change my mind?

The official Q2 guidance beat, continued segment growth, cardiovascular innovation and strategic investments support a constructive long-term case. [#SEC-8K-2026-07-29]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-03

Base target

$52

p=55%

Bull target

$61

p=20%

Bear target

$42

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

WATCHMAN and electrophysiology pressure
Cardiovascular pipeline and strategic investments
The official Q2 guidance beat, continued segment growth, cardiovascular innovation and strategic investments support a constructive long-term case.

BearKey bullets

Clinical, regulatory, launch and strategic-investment execution risks remain material.
Electrophysiology share pressure could weigh on growth through 2027.
No post-print analyst revisions, target changes or detailed market-reaction evidence are available.

WatchKey bullets

Q2 beat company guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $52 (p=55%)

Target spread vs base: +17% / -19%

Scenario probabilities

Bull Target: $61 (p=20%)Base Target: $52 (p=55%)Bear Target: $42 (p=25%)

Commentary

News tone is mixed-positive: the official SEC-filed earnings release confirms a Q2 guidance beat, while secondary stored earnings-call coverage points to a lower near-term outlook. The packet does not provide a post-release price move or analyst revisions, and social data is absent; this supports monitoring rather than a high-conviction upgrade.

As of 2026-08-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

The official Q2 guidance beat, continued segment growth, cardiovascular innovation and strategic investments support a constructive long-term case. [#SEC-8K-2026-07-29]

Bear Case

Drivers

Scannable catalysts and supporting factors

WATCHMAN and electrophysiology pressure
Cardiovascular pipeline and strategic investments

Scenarios

Bull Target (Scenario probability)

$61 / p=20% prob

Base Target (Scenario probability)

$52 / p=55% prob

Bear Target (Scenario probability)

$42 / p=25% prob

Analysis 2026-08-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.35

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-07-29
Q2 beat company guidance
The official Q2 earnings release reported $5.442 billion of revenue, up 7.5% reported and 7.0% organic, with adjusted EPS of $0.86 versus company guidance of $0.82-$0.84. The post-release price reaction is unavailable. [#SEC-8K-2026-07-29]
Prob 100.00% • Move 3.00% • Priced-in 85.00%

Short-term Catalysts

Next few weeks

WATCHMAN and electrophysiology pressure
2026-08-31
Secondary stored earnings-call coverage reports slower WATCHMAN demand and EP share pressure led management to lower the near-term outlook, with 2026 organic growth expected at 5%-6% and adjusted EPS at $3.28-$3.32. This has not been independently confirmed here against a full company transcript. [#PR-EARNINGS-2026-07-30]
Prob 80% • Move -6% • Priced-in 70%

Long-term Catalysts

Months to a year

Cardiovascular pipeline and strategic investments
2027-12-31
The official filing describes the $1.5 billion MiRus investment, an approximately 34% equity stake and an option on the MiRus TAVR business, alongside SEISMIQ and FARAPULSE clinical and product opportunities. [#SEC-8K-2026-07-29] [#SEC-8K-2026-04-22]
Prob 65% • Move 18% • Priced-in 40%

Risks

Clinical, regulatory, launch and strategic-investment execution risks remain material.
Electrophysiology share pressure could weigh on growth through 2027.
No post-print analyst revisions, target changes or detailed market-reaction evidence are available.
The reported revised outlook assumes limited second-half EPS growth and only 0-25 basis points of operating-margin expansion.
WATCHMAN demand and referral-pattern changes may persist.

Peers

Symbol	Summary
EW	The strongest available direct medtech comparator in the packet; no peer financial or post-earnings operating data was supplied, so no relative-performance conclusion is drawn.
ABT	A broader diversified healthcare and medtech comparator; it is retained for context only because the packet lacks company-specific comparative operating evidence.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-03

Loading AI feed…

Symbol

Summary

The strongest available direct medtech comparator in the packet; no peer financial or post-earnings operating data was supplied, so no relative-performance conclusion is drawn.

ABT

A broader diversified healthcare and medtech comparator; it is retained for context only because the packet lacks company-specific comparative operating evidence.